Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
What I have found is that the real value of charts is as a trade management tool.
Holiday shopping is big, but so is holiday eating, and here are several names with healthy dividend yields to chomp into.
What is most notable about sentiment is that there isn't much cheering.